Archived Content
Day 1 | Day 2 | Day 3 | Download Brochure
Wednesday, February 22
7:55 am Chairperson's Remarks
Jake Chen, Ph.D., Associate Professor, Informatics, Indiana University
8:00 Network Polypharmacology in Systems Lead Finding
Jeremy Jenkins, Ph.D., Senior Investigator I, DMP, Quantitative Biology, Chemical Biology Informatics, Novartis Institutes for BioMedical Research
Protein interactomics data provides the basis for network maps that can represent theoretical targets in phenotypic assays. Protein interaction networks as an organizing principle for discovering chemical leads - both alone and in combination - will be presented.
8:30 Translating Systems Biology to Systems Pharmacology: Integrating in vitro Systems Biology and Disease-PKPD Modeling to Advance the Discovery of Antibody Therapeutics
John Burke, Ph.D., Senior Principal Scientist, Head, Systems Biology and Pre-Clinical PKPD Modeling, Translational Research, Boehriniger Ingelheim Pharmaceuticals
First principals Systems Biology modeling and analysis elucidated seemingly contradictory in vitro data via model prediction. The model was then translated into the mechanistic disease-PKPD Systems Pharmacology paradigm to predict optimal therapeutic parameters. As a result, the lead was identified.
9:00 Computational Approaches in Studying Network Pharmacology
Philip E. Bourne PhD, Professor, Pharmacology, University of California, San Diego, Associate Director, RCSB Protein Data Bank, Co-founder & Editor in Chief PLoS Computational Biology
Recent success in using computational network pharmacology to explain unusual outcomes, both positive and negative, that are seen experimentally and/or clinically. Examples will be given, including Nelfinavir. Our approach combines cheminformatics, structural bioinformatics and systems biology.
KEYNOTE PRESENTATION
Sponsored by
9:30 De-Risking Drug Discovery Using Network
Pharmacology
Malcolm Young, Ph.D., CEO, e-Therapeutics
Statistical analysis of current attrition rates shows that preclinical and early clinical stage data do not predict efficacy, safety and deliverability in human patients nearly well enough. Further, and more accurate, ways to de-risk candidates before expensive clinical trials are urgently required.
10:00 Transition to Plenary Keynote
Sponsored by
11:00 Refreshment Break in the Exhibit Hall with Poster Viewing
12:00 pm Modeling Drug Efficacy Using Network Pharmacology
Jake Chen, Ph.D., Associate Professor, Informatics, Indiana University
This will describe how the study of drugs, molecules, and drug-target can benefit predictive modeling of drug effects and evaluations of their efficacy. This opens up new opportunities for future drug development; this new exciting field can revolutionize future drug development.
12:30 EXPERT PANEL: Implementing Network Pharmacology in Current Pharma Strategies: Unveiling & Championing Existing Resources
Moderator:
Jeremy Jenkins, Ph.D., Senior Investigator I, DMP, Quantitative Biology, Chemical Biology Informatics, Novartis Institutes for BioMedical Research
Panelists:
John Burke, Ph.D., Senior Principal Scientist, Head, Systems Biology and Pre-Clinical PKPD Modeling, Translational Research, Boehriniger Ingelheim Pharmaceuticals
Jake Chen, Ph.D., Associate Professor, Informatics, Indiana University
Malcolm Young, Ph.D., CEO, e-Therapeutics
Philip E. Bourne Ph.D, Professor, Pharmacology, University of California, San Diego, Associate Director, RCSB Protein Data Bank, Co-Founder & Editor in Chief PLoS Computational Biology
1:00 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own
2:00 Ice Cream Refreshment Break in the Exhibit Hall with Poster Viewing
Plenary Keynote Panel
2:30 Plenary Keynote Panel
3:50 Refreshment Break & Poster Awards in the Exhibit Hall
4:25 Organizer's Remarks
Kate Skaare, Cambridge Healthtech Institute
4:30 PANEL DISCUSSION: Creating Safety Endpoints as a Milestone within Pharmaceutical Discovery & Development
Moderator: Ernie Bush, Ph.D., Vice President, Collaborative Projects, The Drug Safety Executive Council
Panelists: Dave Watson, Eli Lilly; Michael Forstner, F.Hoffman La Roche, Thomas Schroeter, Pfizer
- Establishing safety assessment endpoints throughout the pipeline
- Why "one fits all" does not work
- Pre-clinical vs. clinical endpoints
KEYNOTE PRESENTATION
5:30 Target Validation of B-Lymphocyte Stimulator and Development of Belimumab—A Case Study
William W. Freimuth, M.D., Ph.D., Vice-President of Clinical Research Immunology, Rheumatology and Infectious Diseases, Human Genome Sciences, Inc.
B-Lymphocyte Stimulator (BLyS) is a member of the TNF ligand super family responsible for the survival of antibody producing B-cells. Its experimental overexpression is associated with an autoimmune phenotype, and its increase in the blood of patients with systemic lupus erythematosus (SLE).
6:30 Close of Day
Day 1 | Day 2 | Day 3 | Download Brochure